Elan (ELN) Stock Price, News & Analysis

Company Overview

Elan Corporation Ltd (Elan), formerly Elan Corporation, plc, is a biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. On February 6, 2013, the Company announced that it has entered into an asset purchase agreement with Biogen Idec to transfer to Biogen Idec all Tysabri IP and other assets related to Tysabri. As of 31 December 2012, there were approximately 72,700

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ELN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Elan own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elan investors own include Home Depot (HD), Merck & Co., Inc. (MRK), Oracle (ORCL), Visa (V), Cisco Systems (CSCO), Alphabet (GOOG) and JPMorgan Chase & Co. (JPM).

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NYSE:ELN
• CIK: 737572
• Web: www.elan.com
• Phone: +353-1-7094000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A